Fig. 2From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapyComparison of DFS(a) and OS(b) curves between patients with different groups (NLR<5, NLR>5). a: Patients with low NLR had longer DFS [HR 2.740 (95% CI, 1.008, 3.680); p < 0.01]; b: Patients with low NLR had longer OS [HR 4.817 (95% CI, 1.572, 4.600); p < 0.01]Back to article page